Nuvectis Pharma
NVCT
Nuvectis Pharma (NVCT) news
Recent news
Nuvectis Pharma - base prospectus covers offer and sale of up to $200 mln of securities - SEC filing
Nuvectis Pharma, Inc. (Nasdaq: NVCT) has filed a base prospectus with the U.S. Securities and Exchange Commission (SEC) covering the potential offer and sale of up to $200 million of its securities. The filing, made under a shelf registration statement on Form S-3 (File No. 333-293459), was…
AInvest Wire · Aug 21, 2026Nuvectis: expected gross proceeds of $100M from offering
AInvest Wire · Jun 30, 2026Nuvectis Pharma prices 5M shares of common stock at $20/shr
AInvest Wire · Jun 30, 2026Nuvectis Pharma prices $100M offering of stock
AInvest Wire · Jun 30, 2026Nuvectis Pharma - suspends sales agreement prospectus; no sales until new filing - SEC filing
AInvest Wire · Jun 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.